Alector, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alector, Inc. (Nasdaq: ALEC) is a clinical-stage biotechnology company focused on developing immuno-neurology therapies to counteract the progression of neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease and Lewy body dementia. Founded in 2013 and headquartered in South San Francisco, California, the company advances a pipeline of antibody, enzyme replacement and siRNA therapeutics leveraging its proprietary Alector Brain Carrier (ABC) technology for enhanced brain delivery; core programs include AL101 (PGRN antibody in Phase 2 for Alzheimer's disease, partnered with GSK), nivisnebart (PGRN x SORT1 antibody in Phase 2 for Alzheimer's), AL002 (TREM2 agonist in Phase 2 for Alzheimer's), AL137 (anti-amyloid beta antibody in preclinical for Alzheimer's), AL050 (GCase-ERT in preclinical for Parkinson's, Gaucher disease and Lewy body dementia), ADP064-ABC (anti-tau siRNA in research for Alzheimer's and frontotemporal dementia), ADP062-ABC (anti-α-synuclein siRNA in research for Parkinson's) and ADP065-ABC (anti-NLRP3 siRNA in research for Alzheimer's and Parkinson's). Alector operates primarily in the United States with global clinical trial activities and strategic collaborations including ongoing partnerships with GSK and historical alliances such as with AbbVie. Recent developments encompass completion of enrollment at approximately 75% in the Phase 2 PROGRESS-AD trial for early Alzheimer's by mid-2025, progression of ABC-enabled candidates targeting clinical entry for ADP037-ABC (anti-amyloid beta) and ADP050-ABC (GCase enzyme) in 2026 pending preclinical results, reporting of $457.2 million in cash reserves as of September 2024 to fund operations through 2026, and mixed clinical outcomes including the failure of partnered latozinemab in a frontotemporal dementia trial in 2025.
Company News
Alector Announces Pricing of Underwritten Offering
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases
Contrasting Alector (NASDAQ:ALEC) & Ionis Pharmaceuticals (NASDAQ:IONS)
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT)
Alector to Participate in Upcoming Healthcare Conferences
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript